ESR1 and neoplasm: In terms of adjuvant therapy, HGASC patients exhibit significantly lower survival rates than other breast cancer subtypes, particularly those with tumor diameters >2 cm, lymph node metastasis, and ER-/PR-negative status, which are associated with higher recurrence risks and shorter disease-free survival (19).